Solentim expands global reach, opening new operation in China

Bournemouth, UK, 23rd February 2021 / Sciad Newswire / Solentim, the trusted global leader in cell therapy workflows enabling the creation, isolation and characterization of high value cells, announces the opening of a new office in Shanghai. Solentim China is a joint venture with its longstanding distribution partner Trio Biotech Co, and will enhance support for customers and expand commercial activity across the region.

Dr Mark Truesdale, CEO, Solentim, said: “I’m pleased to announce the opening of Solentim’s office in Shanghai as China has been a strong market for us for a number of years. This is an opportunity to deliver an even better service to our customers while our expanding product portfolio, including our new ICON product, is opening up new opportunities that can best be serviced locally through our own subsidiary.”

Kun Peng, General Manager of Solentim China, added: “With over 100 customers already in China, this direct investment will help us support and expand our activities, bringing in new technologies for cell therapy and cell line development. Solentim’s technologies for high value cells have made a big impact in the Chinese market over the last few years and with the opening of Solentim China, we look forward to further supporting our customers.”

ENDS

For further information, contact:

Corporate Contacts:
Solentim Ltd
Duncan Borthwick, Global Marketing Manager
T: +44 (0)1202 798510          
E: duncan.borthwick@solentim.com

PR Contact:
Sciad Communications Ltd
Emma Pickup/Richard Anderson
T: +44 (0)20 3405 7892
E: solentim@sciad.com

Notes to Editors

About Solentim
Solentim is the trusted global leader in cell therapy workflows enabling the creation, isolation and characterization of high value cells. In the pursuit of new biological medicines, our data rich portfolio of industry accepted technologies drives accelerated development of Master Cell Banks. For our customers, which include most of the world’s leading pharmaceutical and biotherapeutics companies, we are the partner of choice for facilitating the highest level of assurance in cell line development for therapeutic protein and viral vector production.

Our portfolio of proven and innovative instruments (including VIPS™, Cell Metric^®, Cell Metric^® CLD and ICON™) are designed for single cell cloning and assurance of monoclonality. Combined with enabling reagents (including InstiGRO™ and Leap-In Transposase^®) from our partners, and our unparalleled domain expertise, we transform the speed and efficiency of clonally-derived Master Cell Bank development. Our customers trust in our technology to ensure they are confidently prepared for regulatory review.